



## **Biomarker-Driven Prospective Clinical Trials:**

Clinical Use of Tumor Molecular Determinants  
to Enhance Patient Benefit.



**14th World Conference on Lung Cancer**  
Industry Sponsored Symposium  
Forum Room  
Tuesday, July 5, 2011 7- 8am

**Response DX™**  
Predictive Biomarker Assays



**RESPONSE  
GENETICS**

# 14<sup>th</sup> WCLC - Industry Sponsored Symposium (ISS)

Tuesday, July 5, 2011 7- 8am — Forum Room (Breakfast will be served)

## PRESENTATION SCHEDULE

### **Biomarker-Driven Prospective Clinical Trials:**

Clinical Use of Tumor Molecular Determinants to Enhance Patient Benefit.

Recent advances in prognostic marker discovery and validation.

#### **Dr. Andreas-Claudius Hoffmann**

Recent studies with targeted agents in lung cancer.

#### **Prof. Dr. Christian Manegold**

EEPIC: Use of biomarkers with predictive function in a prospective trial of elderly patients with advanced stage NSCLC.

#### **George Simon, MD, FACP, FCCP**

Registration is free online at:  
[www.Biomarkerdriven.com](http://www.Biomarkerdriven.com)

##### **Dr. Andreas-Claudius Hoffmann**

Department of Medicine (Cancer Research),  
West German Cancer Center,  
University Hospital Essen

##### **Prof. Dr. Christian Manegold**

Department of Surgery,  
University Medical Center Mannheim,  
Heidelberg University

##### **George R. Simon, MD, FACP, FCCP.**

The Burtschy Family Endowed Chair  
in Cancer Research  
Medical University of South Carolina

This presentation was selected by the 14th World Conference on Lung Cancer Programme Committee as an independent educational activity held in conjunction with the 14th World Conference on Lung Cancer. This presentation is not sponsored or endorsed by the IASLC.